Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients
Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients
The study drug, Aprepitant, is currently used to control chemotherapy induced nausea and
 vomiting and is also approved for post-operative nausea and vomiting. The investigators'
 evaluation of it in morbidly obese patients will demonstrate its ability to control nausea
 and vomiting post-operatively in this subset of patients.
The purpose of this study is to evaluate the effectiveness of Aprepitant, also known as
 Emend, in reducing post-operative nausea and vomiting in morbidly obese patients.
 Post-operative nausea and vomiting that occurs in morbidly obese patients can greatly
 increase the chances of complications during the post-operative period. By treating morbidly
 obese patients with Aprepitant, the goal is to reduce the risk of such complications that may
 be induced by nausea and vomiting.
Inclusion Criteria:

 Subjects included in this study must be:

 -  Female

 -  At least 18 years of age

 -  Non-smoking

 -  At high risk for PONV

 -  Obese with a BMI of at least 45 kg/m2

 -  Undergoing upper gastrointestinal surgery requiring postoperative opioid analgesia

 Exclusion Criteria:

 Subjects will be excluded if:

 -  They have a known allergy to Aprepitant or Ondansetron

 -  They are currently taking Orap (pimozide), Seldane (terfenadine), Hismanal
 (astemizole), or Propulsid (cisapride)

 -  They are pregnant

 -  They are breastfeeding

 -  They plan on getting pregnant in the 2 months following surgery

 -  They are not able to receive patient controlled analgesia (PCA) following surgery

 -  They have a known drug or alcohol abuse problem

 -  They have chronic nausea and vomiting